Armed With Three New Compounds, Glenmark Readies for More Out-licensing Opportunities
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Braving a tough economic environment, India's Glenmark Pharmaceuticals is ramping up its line-up of early-stage compounds with the aim of licensing them out to interested multinational companies